Ketamine is a dissociative anesthetic and analgesic belonging to the arylcyclohexylamine class, originally developed by Parke-Davis and approved for medical use in 1970. As the world's most widely used anesthetic in both human medicine and veterinary practice, ketamine occupies an unusual position among psychoactive substances — it is simultaneously a legitimate, indispensable medical tool and a substance with significant recreational use and dependence potential. Its primary pharmacological mechanism is antagonism of NMDA (N-methyl-D-aspartate) glutamate receptors, producing dose-dependent effects ranging from dissociative analgesia at subanesthetic doses to complete sensory dissociation — the "k-hole" — at higher doses.
At recreational doses, ketamine produces a characteristic dissociative state: a sense of detachment from body and environment, altered perception of time and space, analgesia, and at higher doses, profound alterations in the sense of self extending to what users describe as "ego death" or entry into other realms of consciousness. Community experience places the k-hole — the deep dissociative state achieved with large doses — as ketamine's defining experience, fundamentally different in character from its lower-dose, more functional effects. Reddit users consistently describe the k-hole as "unlike any other drug experience," a formless, ego-dissolved state of pure consciousness that can feel like dying and being reborn. Unlike many psychedelics, ketamine's short duration (45–90 minutes for IM, 20–45 minutes for insufflation) makes it highly controllable, though this brevity also facilitates compulsive redosing.
Ketamine's medical profile includes its use as an induction agent for general anesthesia (particularly in hemodynamically compromised patients), an analgesic for procedural pain and chronic pain management, and increasingly as a rapid-acting antidepressant. Esketamine (Spravato), the S-enantiomer of ketamine, received FDA approval in 2019 for treatment-resistant depression and major depressive disorder with acute suicidal ideation — marking the first fundamentally new antidepressant mechanism approved in decades. The antidepressant effect appears within hours of administration, contrasting sharply with the weeks required by conventional antidepressants.
Ketamine's harm profile is substantially more complex than many other dissociatives. Psychological dependence develops readily, and community experience emphasizes repeatedly that addiction is "frequently and badly underestimated." Bladder toxicity — ketamine-induced uropathy, an irreversible condition characterized by bladder shrinkage, fibrosis, and potentially requiring cystectomy — is a uniquely severe long-term risk associated with frequent, high-dose use. This risk separates ketamine from most other psychedelics and dissociatives in terms of serious physical harm potential.
